| Item type |
学内発行雑誌 / Departmental Bulletin Paper(1) |
| 公開日 |
2016-12-17 |
| タイトル |
|
|
タイトル |
Retrospective Analysis of Clinical Factors Relating to the Outcome of Gemtuzumab Ozogamicin Therapy |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ |
departmental bulletin paper |
| 著者 |
ARIIZUMI, Hirotsugu
SAITO, Bungo
NAKASHIMA, Hidetoshi
HATTORI, Norimichi
MAEDA, Takashi
NAKAMAKI, Tsuyoshi
TOMOYASU, Shigeru
|
| 書誌情報 |
The Showa University journal of medical sciences
巻 23,
号 2,
p. 75-87,
発行日 2011-06
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
It is difficult to predict the clinical outcome of gemtuzumab ozogamicin (GO) therapy based solely on the previously identified predictive factors. We retrospectively analyzed the relationship between clinical factors and outcomes in 12 patients with relapsed or refractory acute leukemia who received GO monotherapy. The median patient age at initial GO infusion was 56 years, and the average initial dosage was 8.1 mg/m2. Four patients (33%) achieved an overall remission (OR). The time from diagnosis to GO infusion was significantly longer in patients with OR than in patients with no remission (NR)(1747 vs. 501 days, respectively; P < 0.01). The number of karyotype abnormalities before GO infusion was significantly greater in NR patients (9.5) than in OR patients (0.5; P = 0.03). Monocyte counts in the bone marrow before GO therapy were significantly lower in OR than in NR patients (100/μL vs. 1080/μL, respectively; P = 0.048). In a multivariate analysis, monocyte count was significantly associated with overall survival (P = 0.005). CD14 expression in OR patients was lower than in NR patients, with the exception of 4 patients whose French-American-British subtypes were M4 or M5 (OR, 0.3%; NR, 2.5%; P = 0.04). NR was noted in all 6 patients who underwent allogeneic stem cell transplantation before and/or after GO infusion. Patients showing good sensitivity to conventional chemotherapy with good survival after diagnosis tend to be sensitive to GO as well. A low monocyte count in the bone marrow at infusion of GO might indicate improved efficacy of GO therapy. Further investigation is warranted for establishing appropriate patient selection and for clarifying efficient conditions for GO therapy. |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
関連識別子 |
10.15369/sujms.23.75 |
| 出版者 |
|
|
出版者 |
Showa Medical Association and Showa University |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0915-6380 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
S23_75.pdf (93.8 kB)
